,Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30
,Cumulative Foreign Currency Translation Adjustments,Cumulative Foreign Currency Translation Adjustments,Net Actuarial Losses and Prior Service Costs and Credits,Net Actuarial Losses and Prior Service Costs and Credits,Cumulative Unrealized Gains on Marketable Equity Securities,Cumulative Unrealized Gains on Marketable Equity Securities,Cumulative Gains on Derivative Instruments Designated as Cash Flow Hedges,Cumulative Gains on Derivative Instruments Designated as Cash Flow Hedges
(dollars in millions),2013,2012,2013,2012,2013,2012,2013,2012
"Balance at December 31, 2012 and 2011",(79),(73),(3596),(2731),31,38,50,167
Separation of AbbVie,(208),(8),1351,66,—,(26),8,(5)
Other comprehensive income (loss) before reclassifications,(330),(136),(227),—,17,9,(8),(11)
Income (loss) amounts reclassified from accumulated other comprehensive income (a),—,(36),82,111,(21),(1),(26),(75)
Net current period comprehensive income (loss) from continuing operations,(330),(172),(145),111,(4),8,(34),(86)
Balance at September 30,(617),(253),(2390),(2554),27,20,24,76